Increased nuclear factor-κB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-α

Journal of Rheumatology

Volumn 34, Issue 10, 2007, Pages 1976-1983

  Dichamp, Isabelle ^a   Bourgeois, Alain ^a   Dirand, Carine ^a   Herbein, Georges ^a   Wendling, Daniel ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Monocytes; Nuclear factor B; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MONOCYTE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

ADULT; AGED; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35148896467     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003;9:1245-50.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
3. Barnes PJ, Karin M. Nuclear factor-kappa-B. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
4. Muller-Ladner U, Gay RE, Gay S. Role of nuclear factor kappa-B in synovial inflammation. Curr Rheumatol Rep 2002;4:201-7.
5. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986;83:8749-53.
6. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
7. Crotti TN, Smith MD, Weedon H, et al. Receptor activator NF-kappa-B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61:1047-54.
8. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-7.
9. Baldwin AS Jr. The NF-kappa B and I-kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
10. Chen F, Castranova V, Shi X, Shi X, Demers LM. New insights into the role of nuclear factor-kappa-B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17.
11. Stancovski I, Baltimore D. NF-kappa-B activation: the I kappa-B kinase revealed? Cell 1997;91:299-302.
12. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of I-kappa-B-alpha by a novel ubiquitination-dependent protein kinase activity. Cell 1996;84:853-62.
13. DiDonato J, Mercurio F, Rosette C, et al. Mapping of the inducible I-kappa-B phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 1996;16:1295-304.
14. Siebenlist UG, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994;10:405-55.
15. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995;80:529-32.
16. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kappa-B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
17. Campbell IK, Gerondakis S, O'Donnel K, Wicks IP. Distinct roles for the NF-kappa-B1 (p50) and c-Re1 transcription factors in inflammatory arthritis. J Clin Invest 2000;105:1799-806.
18. Tak PP, Firestein GS. NF-kappa-B: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
19. Auphan N, DiDonato JA, Rosette C. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
20. Scheinman RI, Cogswell PC, Lofquist AK. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
21. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-9.
22. Bucala R, Ritchlin C, Winchester R. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med 1991;173:569-74.
23. Herbein G, Gordon S. 55- and 75-kilodalton tumor necrosis factor receptors mediate distinct actions in regard to human immunodeficiency virus type 1 replication in primary human macrophages. J Virol 1997;71:4150-6.
24. Yao J, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappa-B transcription factors. J Biol Chem 1997;272:17795-801.
25. Deng GM, Verdrengh M, Liu ZQ, Tarkowski A. The major role of macrophages and their product tumor necrosis factor alpha in the induction of arthritis triggered by bacterial DNA containing CpG motifs. Arthritis Rheum 2000;43:2283-9.
26. Iwahashi M, Yamamura M, Aita T, et al. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004;50:1457-67.
27. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-kappa-B interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 1998;273:21178-86.
28. Tang X, Fenton MJ, Amar S. Identification and functional characterization of a novel binding site on TNF-alpha promoter. Proc Natl Acad Sci USA 2003;100:4096-101.
29. Mahlknecht U, Will U, Varin A, Hoelzer D, Herbein G. Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 2004;173:3979-90.
30. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
31. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
32. Youn J, Kim HY, Park JH, et al. Regulation of TNF-alpha-mediated hyperplasia through TNF receptors, TRAFs, and NF-kappa-B in synoviocytes obtained from patients with rheumatoid arthritis. Immunol Lett 2002;83:85-93.
33. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Skowronski J, Chwieko J. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003;62:472-5.
34. Wendling D, Toussirot E. Anti-TNF alpha therapy in ankylosing spondylitis. Exp Opin Pharmacother 2004;5:1497-507.
35. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
36. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria. Arthritis Rheum 1984;27:361-8.
37. Varin A, Manna SK, Quivy V, et al. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem 2003;278:2219-27.
38. De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNF-alpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005;206:17-27.
39. Jimenez-Boj E, Redlich K, Turk B, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 2005;175:2579-88.
40. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Transcriptional roles of CCAAT/enhancer binding protein-beta, nuclear factor-kappa-B, and C-promoter binding factor 1 in interleukin (IL)-1-beta-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes. J Biol Chem 1998;273:7620-7.
41. Georganas C, Liu H, Perlman H, Hoffman A, Thimapaya B, Pope RM. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol 2000;165:7199-206.
42. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634-5.
43. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-24.
44. Deng GM, Zheng L, Chan FK, Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005;11:1066-72.
45. Lehmann T, Nguyen LQ, Handel ML. Synovial fluid induced nuclear factor-kappa-B DNA binding in a monocytic cell line. J Rheumatol 2000;27:2769-76.
46. McEvoy AN, Murphy EA, Ponnio T, et al. Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5′- monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol 2002;168:2979-87.
47. Grall F, Gu X, Tan L, et al. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappa-B-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003;48:1249-60.
48. Tanaka M, Fuentes ME, Yamaguchi K, Gilbert DJ, Jenkins NA, Miyajima A. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 1999;10:421-9.
49. Aupperle KR, Bennett BL, Boyle DL, Tak PP, Manning AM, Firestein GS. NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes. J Immunol 1999;163:427-33.
50. Criscione LG, St. Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-11.
51. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
52. Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosua T, Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:681-7.
53. Guidi L, Costanzo M, Ciarniello M, et al. Increased levels of NF-kappa-B inhibitors (I-kappa-B-alpha and I-kappa-B-gamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment. Int J Immunopathol Pharmacol 2005;18:155-64.